[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100238186":3},{"organization":4,"armGroups":7,"interventions":37,"overallOfficials":59,"centralContacts":63,"locations":69,"responsibleParty":86,"collaborators":89,"id":92,"slug":93,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":100,"sex":101,"minAge":10,"maxAge":10,"enrollmentInfo":102,"targetDuration":105,"studyType":106,"phases":10,"briefSummary":107,"conditions":108,"keywords":114,"overallStatus":72,"whyStopped":10,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},{"fullName":5,"class":6},"University Hospital Goettingen","OTHER",[8,12,22,26,30,33],{"label":9,"type":10,"description":11,"interventionNames":10},"no-T: untreated patients",null,"untreated patients, typically uncles or grandfathers of present patients. No Intervention (means no therapy until CKD stage V, on renal replacement therapy)",{"label":13,"type":10,"description":14,"interventionNames":15},"T-III: late therapy in patients","patients treated with medications with low eGFR (below 60 ml\u002Fmin) (starts at patients with CKD stages III and IV).",[16,17,18,19,20,21],"Drug: ACE-inhibitor","Drug: Angiotensin-receptor blocker (ARB)","Drug: HMG-Coenzyme inhibitor (statin)","Drug: Spironolactone or Finerenone","Drug: Paricalcitol","Drug: SGLT2 inhibitor",{"label":23,"type":10,"description":24,"interventionNames":25},"T-II: early therapy in patients","therapy starts in patients with albuminuria \\>300mg\u002FgCreatinine and eGFR higher than 60 ml\u002Fmin.",[16,17,18,19,20,21],{"label":27,"type":10,"description":28,"interventionNames":29},"T-I: very early therapy in patients","therapy starts in patients with microhematuria only (usually at birth) or microalbuminuria (30-300 mg albumin per gCreatinine).",[16,17,18,19,20,21],{"label":31,"type":10,"description":32,"interventionNames":10},"no therapy in heterozygous patients","heterozygous patients without therapy",{"label":34,"type":10,"description":35,"interventionNames":36},"therapy in heterozygous patients","heterozygous patients with therapy (which also can be divided into subgroups stage T-0, I, II, III)",[16,17,18,19,20,21],[38,43,46,49,52,56],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":10},"DRUG","ACE-inhibitor","observational study",[27,23,13,34],{"type":39,"name":44,"description":41,"armGroupLabels":45,"otherNames":10},"Angiotensin-receptor blocker (ARB)",[27,23,13,34],{"type":39,"name":47,"description":41,"armGroupLabels":48,"otherNames":10},"HMG-Coenzyme inhibitor (statin)",[27,23,13,34],{"type":39,"name":50,"description":41,"armGroupLabels":51,"otherNames":10},"Spironolactone or Finerenone",[27,23,13,34],{"type":39,"name":53,"description":54,"armGroupLabels":55,"otherNames":10},"Paricalcitol","observational study!",[27,23,13,34],{"type":39,"name":57,"description":41,"armGroupLabels":58,"otherNames":10},"SGLT2 inhibitor",[27,23,13,34],[60],{"name":61,"affiliation":5,"role":62},"Oliver Gross, MD","PRINCIPAL_INVESTIGATOR",[64],{"name":61,"role":65,"phone":66,"phoneExt":67,"email":68},"CONTACT","+49-551-39-","60488","gross.oliver@med.uni-goettingen.de",[70],{"facility":71,"status":72,"city":73,"state":74,"zip":75,"country":76,"countryCode":77,"cosmosGeoPoint":78,"geoPoint":83,"contacts":84},"University Medical Center Göttingen","RECRUITING","Göttingen","Lower Saxony","37075","Germany","DE",{"type":79,"coordinates":80},"Point",[81,82],9.93228,51.53443,{"lat":82,"lon":81},[85],{"name":61,"role":65,"phone":66,"phoneExt":67,"email":68},{"type":62,"investigatorFullName":87,"investigatorTitle":88,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Prof. Dr. O. Gross","Prof. Dr. Oliver Gross",[90],{"name":91,"class":6},"Society for Pediatric Nephrology (Germany)","100238186","alport-therapy-registry---european-initiative-towards-delaying-renal-failure-in-alport-syndrome-100238186",false,"NCT02378805","Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome","European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome: Current and Novel Therapies","Alport-XXL","Inclusion Criteria:\n\nDiagnosis of Alport syndrome (AS) by kidney biopsy or mutation analysis (or both).\n\nAny type of genetic variant is accepted for X-linked, autosomal or digenic Alport syndrome (COL4A3, 4 or 5 genes).\n\nExclusion criteria:\n\nPatients not willing to give informed consent. Patient with suspected diagnosis, whcih cannot be confirmed.",true,"ALL",{"count":103,"type":104},800,"ESTIMATED","30 Years","OBSERVATIONAL","The hereditary type IV collagen disease Alport syndrome leads to kidney failure early in life. Currently there are no specific medications approved for treatment, however, several therapies have been evaluated preclinically and could improve outcome. For that reason, this non-interventional, observational study investigates, if medications (1) delay disease progression; (2) delay time to kidney failure; (3) improve life-expectancy compared to untreated patients (relatives). This observational study started in 2006 as an European registry. Since 2019, this registry has been expanded to \"Alport XXL\" via the International Alport Alliance as a global effort across all continents. From 2020 on to present, \"Alport XXL\" has a special focus on the outcomes of early therapy in young patients on ACE-inhibitors vs. Angiotensin-receptor blockers vs. their combination.",[109,110,111,112,113],"Alport Syndrome","Hereditary Kidney Disease","Pediatric Kidney Disease","Thin Basement Membrane Disease","Familial Benign Hematuria",[115,116,117],"Alport syndrome","thin basement membrane disease","familial benign hematuria","2025-03-03",{"date":120,"type":121},"2025-03-06","ACTUAL",{"date":123,"type":10},"1995-07",{"date":125,"type":104},"2036-03-01",{"name":5,"class":6},1]